Search

Your search keyword '"Koschmieder, Anja"' showing total 7 results
Start Over Author "Koschmieder, Anja"
7 results on '"Koschmieder, Anja"'

1. Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomes

Author

Krug, Utz, Röllig, Christoph, Koschmieder, Anja, Heinecke, Achim, Sauerland, Maria Cristina, Schaich, Markus, Thiede, Christian, Kramer, Michael, Braess, Jan, Spiekermann, Karsten, Haferlach, Torsten, Haferlach, Claudia, Koschmieder, Steffen, Rohde, Christian, Serve, Hubert, Wörmann, Bernhard, Hiddemann, Wolfgang, Ehninger, Gerhard, Berdel, Wolfgang E, Büchner, Thomas, and Müller-Tidow, Carsten

Published
2010
Full Text
View/download PDF

2. Feasibility of azacitidine added to standard chemotherapy in older patients with acute myeloid leukemia - a randomised SAL pilot study

Author

Krug, Utz, Koschmieder, Anja, Schwammbach, Daniela, Gerss, Joachim, Tidow, Nicola, Steffen, Björn, Bug, Gesine, Brandts, Christian H., Schaich, Markus, Röllig, Christoph, Thiede, Christian, Noppeney, Richard, Stelljes, Matthias, Büchner, Thomas, Koschmieder, Steffen, Dührsen, Ulrich, Serve, Hubert, Ehninger, Gerhard, Berdel, Wolfgang E., Müller-Tidow, Carsten, and Universitäts- und Landesbibliothek Münster

Subjects
Acute Myeloid Leukemia, Male, Maximum Tolerated Dose, Cancer Treatment, Medizin, lcsh:Medicine, Pilot Projects, Epigenetic Therapy, Hematologic Cancers and Related Disorders, Leukemias, Antineoplastic Combined Chemotherapy Protocols, Humans, ddc:610, lcsh:Science, Aged, Daunorubicin, lcsh:R, Cytarabine, Cancers and Neoplasms, Hematology, Induction Chemotherapy, Chemotherapy and Drug Treatment, Middle Aged, Survival Analysis, Consolidation Chemotherapy, Leukemia, Myeloid, Acute, Treatment Outcome, Oncology, Medicine and health, Azacitidine, Medicine, Feasibility Studies, Female, lcsh:Q, Research Article
Abstract

Introduction: Older patients with acute myeloid leukemia (AML) experience short survival despite intensive chemotherapy. Azacitidine has promising activity in patients with low proliferating AML. The aim of this dose-finding part of this trial was to evaluate feasibility and safety of azacitidine combined with a cytarabine- and daunorubicin-based chemotherapy in older patients with AML. Trial Design: Prospective, randomised, open, phase II trial with parallel group design and fixed sample size. Patients and Methods: Patients aged 61 years or older, with untreated acute myeloid leukemia with a leukocyte count of ,20,000/ml at the time of study entry and adequate organ function were eligible. Patients were randomised to receive azacitidine either 37.5 (dose level 1) or 75 mg/sqm (dose level 2) for five days before each cycle of induction (7+3 cytarabine plus daunorubicine) and consolidation (intermediate-dose cytarabine) therapy. Dose-limiting toxicity was the primary endpoint. Results: Six patients each were randomised into each dose level and evaluable for analysis. No dose-limiting toxicity occurred in either dose level. Nine serious adverse events occurred in five patients (three in the 37.5 mg, two in the 75 mg arm) with two fatal outcomes. Two patients at the 37.5 mg/sqm dose level and four patients at the 75 mg/sqm level achieved a complete remission after induction therapy. Median overall survival was 266 days and median event-free survival 215 days after a median follow up of 616 days. Conclusions: The combination of azacitidine 75 mg/sqm with standard induction therapy is feasible in older patients with AML and was selected as an investigational arm in the randomised controlled part of this phase-II study, which is currently halted due to an increased cardiac toxicity observed in the experimental arm. Trial Registration: This trial is registered at clinical trials.gov (identifier: NCT00915252).

Published
2012

3. Azacitidine Followed By Intensive Induction/Consolidation Chemotherapy in Older Patients with Acute Myeloid Leukemia (AML): Results from the Randomized AML-AZA Trial of the Study Alliance Leukemias (SAL)

Author

Müller-Tidow, Carsten, primary, Tschanter, Petra, additional, Krug, Utz, additional, Goellner, Stefanie, additional, Röllig, Christoph, additional, Thiede, Christian, additional, Koschmieder, Anja, additional, Dugas, Martin, additional, Gerss, Joachim, additional, Butterfaß-Bahloul, Trude, additional, Wagner, Ruth, additional, Krause, Stefan W., additional, Kaiser, Ulrich, additional, Kunzmann, Volker, additional, Steffen, Björn, additional, Noppeney, Richard, additional, Herr, Wolfgang, additional, Baldus, Claudia D, additional, Schmitz, Norbert, additional, Götze, Katharina, additional, Reichle, Albrecht, additional, Kaufmann, Martin, additional, Neubauer, Andreas, additional, Schäfer-Eckart, Kerstin, additional, Hänel, Mathias, additional, Peceny, Rudolf, additional, Bea, Haack, additional, Meredith, Lilly, additional, Frickhofen, Norbert, additional, Kiehl, Michael G, additional, Giagounidis, Aristoteles A.N., additional, Görner, Martin, additional, Repp, Roland, additional, Naumann, Ralph, additional, Link, Hartmut, additional, Kiani, Alexander, additional, Koschmieder, Steffen, additional, Brümmendorf, Tim H., additional, Serve, Hubert, additional, Ehninger, Gerhard, additional, and Berdel, Wolfgang E, additional

Published
2014
Full Text
View/download PDF

4. Feasibility of Azacitidine Added to Standard Chemotherapy in Older Patients with Acute Myeloid Leukemia — A Randomised SAL Pilot Study

Author

Krug, Utz, primary, Koschmieder, Anja, additional, Schwammbach, Daniela, additional, Gerss, Joachim, additional, Tidow, Nicola, additional, Steffen, Björn, additional, Bug, Gesine, additional, Brandts, Christian H., additional, Schaich, Markus, additional, Röllig, Christoph, additional, Thiede, Christian, additional, Noppeney, Richard, additional, Stelljes, Matthias, additional, Büchner, Thomas, additional, Koschmieder, Steffen, additional, Dührsen, Ulrich, additional, Serve, Hubert, additional, Ehninger, Gerhard, additional, Berdel, Wolfgang E., additional, and Müller-Tidow, Carsten, additional

Published
2012
Full Text
View/download PDF

5. Estimating the Chances of Older AML Patients to Achieve a Complete Remission Upon Intensive Induction Chemotherapy - An AMLCG and SAL Study

Author

Krug, Utz O, primary, Rohde, Christian, additional, Heinecke, Achim, additional, Sauerland, Maria Cristina, additional, Koschmieder, Anja, additional, Röllig, Christoph, additional, Schaich, Markus, additional, Thiede, Christian, additional, Kramer, Michael, additional, Braess, Jan, additional, Spiekermann, Karsten, additional, Haferlach, Torsten, additional, Haferlach, Claudia, additional, Ehninger, Gerhard, additional, Woermann, Bernhard Josef, additional, Berdel, Wolfgang E., additional, Hiddemann, Wolfgang, additional, Buchner, Thomas, additional, and Müller-Tidow, Carsten, additional

Published
2010
Full Text
View/download PDF

6. Addition of 5-Azacitidine to Standard Induction Therapy Is Feasible In Older Patients with Acute Myeloid Leukemia: The AML-AZA Trial of the SAL Study Group

Author

Krug, Utz O, primary, Koschmieder, Anja, additional, Gerss, Joachim, additional, Serve, Hubert, additional, Steffen, Björn, additional, Bug, Gesine, additional, Schaich, Markus, additional, Brandts, Christian, additional, Röllig, Christoph, additional, Ehninger, Gerhard, additional, Duehrsen, Ulrich, additional, Noppeney, Richard, additional, Berdel, Wolfgang E., additional, Koschmieder, Steffen, additional, and Müller-Tidow, Carsten, additional

Published
2010
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results